In May 2009, despite promise of new antibiotic development, Cumbre Pharmaceuticals described as "a once-promising drug development company that burned through millions in venture capital funding â was officially dissolved, nearly four months after it closed shop at its headquarters, Management noted that âThe company gave it go â and it didnât work â and it dissolvedâ Cumbre Pharmaceuticals is a biopharmaceutical company that is dedicated to meeting the challenge of infectious disease in the new millennium. Cumbre discovers, develops and commercializes novel classes of antimicrobial drugs for the treatment of bacterial and fungal infections. Such infections represent a serious and growing medical problem in both hospital and community settings. Cumbre combines a proprietary proteomics-based drug discovery technology with target-directed screens and a lead compound series. Cumbre Pharmaceuticals was a spinout of
